{
  "variants": [
    {
      "variant": "G2019S",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "The paper establishes a clear link between LRRK2 kinase activity and Parkinson's disease (PD). Mutations affecting kinase activity (e.g., G2019S) are directly tied to PD pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "The KESTREL screen and kinase activity assays are directly relevant to the disease mechanism (kinase activity modulates PD risk)."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls (e.g., G2019S vs. non-pathogenic variants) and reports experiments conducted in triplicate."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., G2019S) and benign variants (e.g., R1441C) are used as controls in the assays."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max PS3_supporting."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant": "R1941H",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, and mutations affecting activity (e.g., R1941H) are tied to pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., R1941H) and benign variants are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max PS3_supporting."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant": "I2012T",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, and mutations affecting activity (e.g., I2012T) are tied to pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., I2012T) and benign variants are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max PS3_supporting."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant": "I2020T",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, and mutations affecting activity (e.g., I2020T) are tied to pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., I2020T) and benign variants are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max PS3_supporting."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant": "G2385R",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, and mutations affecting activity (e.g., G2385R) are tied to pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., G2385R) and benign variants are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max PS3_supporting."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant": "R1441C",
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, but mutations with no effect (e.g., R1441C) are not associated with pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., R1941H) and benign variants (e.g., R1441C) are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max BS3_supporting."
        }
      ],
      "final_strength": "BS3_supporting"
    },
    {
      "variant": "R1441G",
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, but mutations with no effect (e.g., R1441G) are not associated with pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., R1941H) and benign variants (e.g., R1441G) are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max BS3_supporting."
        }
      ],
      "final_strength": "BS3_supporting"
    },
    {
      "variant": "Y1699C",
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "description": "LRRK2 kinase activity modulates PD risk, but mutations with no effect (e.g., Y1699C) are not associated with pathogenesis."
        },
        {
          "step": "Step 2: Evaluate assay applicability",
          "description": "Kinase activity assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3a: Basic controls and replicates",
          "description": "The study uses wild-type and mutant controls and replicates experiments."
        },
        {
          "step": "Step 3c: Variant controls",
          "description": "Known pathogenic variants (e.g., R1941H) and benign variants (e.g., Y1699C) are used as controls."
        },
        {
          "step": "Step 4b: Control variant counts",
          "description": "The study uses 8 control variants (4 pathogenic/inhibitory, 4 neutral). Since this is <11, the strength is Max BS3_supporting."
        }
      ],
      "final_strength": "BS3_supporting"
    }
  ]
}